about
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis PigmentosaA Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis PigmentosaA Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular DegenerationLaser-Ranibizumab-Triamcinolone for Proliferative Diabetic RetinopathyLaser-Ranibizumab-Triamcinolone for Diabetic Macular EdemaIntravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular EdemaSafety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment UveitisA Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular AttachmentOpen-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMDSafety and Efficacy of Emixustat in Stargardt DiseaseStudy of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal DetachmentSafety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis PigmentosaEfficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular DegenerationA Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular EdemaA Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationSuprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
P6153
Q61924249-ECEDA105-CD87-475C-93E5-7A1152F848CDQ61924250-25095AF2-BAEA-49EE-A4C6-0C3811BCF0F8Q61924253-7754DFA7-2845-442E-89F2-88A7E97D8035Q61924668-485EF3B8-838C-489A-A67C-8BE75ACA2DAEQ61924722-D92606E1-DF10-47F4-97D6-8BBB5D3FE7F6Q61933964-99FF5D84-4B60-48AE-8738-9DBE74A2973BQ61957172-7D709639-F8BE-4D7F-8654-EA9E3F25695DQ61975681-2CB49604-30EC-4FCF-A822-2F2B0448C6FBQ61979399-20599052-62C4-4E80-A17A-F29900AB1D98Q62031156-98F029CE-024F-4C34-9FD6-983CB5109C03Q62105358-11B7F8C2-DD83-44E8-8F4F-DCB6BD184B62Q62110839-389803C1-1EDC-4D8A-95D8-6E61FEDB827CQ63228846-6CFAAFCF-5B84-4EFF-9A30-68B711C28EC8Q63315610-B9FD454D-3A5D-4734-A1B9-75C8D75F6A66Q63393863-A186296F-41DC-4AEA-BE2A-073949858040Q63534973-EC1B9D3B-86E9-49EB-9EFC-855F4472E655Q63571435-F5FA0DDE-D923-4876-8759-96B81E8234F5Q64216774-0B921473-E682-442C-B34D-E02A3338D3B5
P6153
description
healthcare organization in Beverly Hills, United States
@en
name
Retina Vitreous Associates Medical Group
@en
type
label
Retina Vitreous Associates Medical Group
@en
prefLabel
Retina Vitreous Associates Medical Group
@en
P131
P2427
grid.452717.2
P571
1982-01-01T00:00:00Z
P625
Point (-118.344346 33.830654)